Company
IMT provides advanced medical solutions for non-invasive liver fibrosis diagnosis based on MRI and AI technologies. The current gold standard for liver fibrosis diagnosis is liver biopsy, which is invasive and impractical for screening and treatment monitoring. The existing non-invasive diagnostic techniques still have significant limitations. We aim to develop a product to fill the gap of liver fibrosis diagnosis. Our solutions are convenient and easy to operate. They are clinically tested to ensure high robustness and effectiveness.
Technology
Our product is based on MRI. It is non-invasive, has no ionized radiation, and does not need to inject any contrast agent. Our product runs on standard clinical MRI scanners and does not need any extra hardware. Our product is software. It consists of two components. The first component is an MRI application for data acquisition, which is installed on a standard clinical MRI scanner. The second component is AI-based post-processing and analysis software which is provided as a cloud platform. The MRI scan of data acquisition takes only a few brief breath-hold with each no more than 8 seconds. After the MRI scan is completed, the Dicom images are sent to the cloud for automatic analysis and generate a clinical report for doctors' assessment.
